Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Document › Details

AMS Biotechnology (Europe) Ltd.. (7/6/18). "Press Release: AMSBIO and University of Strathclyde Jointly Launch New Screening Company".

Region Region Glasgow
  Country United Kingdom (GB)
Organisations Organisation ScreenIn3D Ltd.
  Group AMSBIO (AMS Biotechnology) (Group)
  Organisation 2 University of Strathclyde (Glasgow)
Products Product OncoScreen service (microfluidic 3D culture screening platform)
  Product 2 3D cell culture technology
Index term Index term AMS Biotechnology–Univ Strathclyde: drug screening technology, 201807 collab establishment of joint venture ScreenIn3D in Glasgow
Person Person Sim, Alex (AMS Biotechnology 201007)

ScreenIn3D (Glasgow, UK) is a new joint venture company set up by AMSBIO and the University of Strathclyde exploiting the latest advances in microfluidics and 3D culture to develop a novel microfluidic screening platform.

The unique combination of microfluidic lab-on-a-chip technology with physiologically relevant 3D spheroids is designed to make drug discovery more closely relevant with what happens in the body. The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies do 100x more testing for the same money spent as well as increasing productivity as it enables more experiments to be done on the same platform at the same time.

OncoScreen service - the first application platform launched by ScreenIn3D is targeted at improving anticancer drug treatment and accelerating development of new personalized medicine solutions using patient-derived tissue.

Chosen by the Society for Laboration Automation & Screening (SLAS Europe) as an exciting innovation technology company (presented at SLAS Europe 2018), the ONCOSCREEN service offers users the ability to reduce and replace animal models in cancer research. As well as offering 100-fold greater throughput than existing cancer screening assays for same cost – ONCOSCREEN also provides a larger screening capability of patient-derived tissue than any existing services.

Alex Sim, Managing Director of AMSBIO and ScreenIn3D said:
The OncoScreen platform presents exciting possibilities for testing patient-derived multicellular tumor spheroids/organoids (comprising cancer cells, stromal cells, cancer stem cells and/or immune cells) for disease/biomarker-oriented drug activity and profiling using single- and pair-wise standard/targeted drug combinations”.

He added:
We are actively seeking partners and investors to fast track development of further platforms. Additional R&D grants to enhance our immunotherapy and neuroscience programs are being applied for with our collaborators."

Record changed: 2018-07-10


Picture [iito] Plain Stupid Simple 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top